US Ketamine Clinics Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
US · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$1.34 BnPlaceholder estimate
Estimate 2025$1.44 Bn37.3% of the global market
Projected 2034$2.79 Bn 93.3%Adds $1.35 Bn over 9 forecast years
CAGR 2025–20347.6%Faster than 57% of 107 Healthcare Services markets here
Key players5
US is 37.26% of the global market.
In North America, the largest is US (this report) at $1.44 Bn.
Johnson & Johnson, Klarity Health, Mindbloom, Nushama, Novamind (see all)
Active clinical trials
50 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The US Ketamine Clinics Market Analysis Executive Summary
Ketamine clinics give ketamine or esketamine treatments under medical supervision for depression and other mental health conditions.
Key segments of the ketamine Clinics market include treatment (IV Ketamine, Intranasal Esketamine and Ketamine-Assisted Psychotherapy) and indication (Depression, PTSD and Chronic Pain).
US Ketamine Clinics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
US Ketamine Clinics Market Dynamics
Market Growth Drivers
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the ketamine Clinics market. Governments and employers are investing more in mental health care.
Opportunity
Digital tools, new drug classes and care built into primary care and workplaces give the ketamine Clinics market strong room to grow worldwide.
Market Restraints
Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the ketamine Clinics market.
Competitive Landscape for Ketamine Clinics Market in US
The ketamine Clinics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Ketamine Clinics Market in US
Ketamine Clinics in the US: payment and research
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).[1] ClinicalTrials.gov lists 50 studies on Ketamine Clinics that are recruiting, active or about to start in the US.[2] Suicide rate: 14.0 per 100,000 people in 2023, the latest WHO figure for the US.[3]
Licensing, quality standards and payment models from public and private payers shape how ketamine Clinics services are delivered and paid for in US. Government health programs and insurance coverage are key to access.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Treatment
4.2 By Indication
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Johnson & Johnson (Janssen)
7.2 Klarity Health
7.3 Mindbloom
7.4 Nushama
7.5 Novamind
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The ketamine Clinics market can be segmented based on various criteria, including treatment, indication and end user. Here's a breakdown of the market segmentation
Placeholder estimate: about $1.44 Bn in 2025, rising to about $2.79 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Ketamine Clinics market in the US growing?
Placeholder estimate: about 7.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Ketamine Clinics market report cover?
The report splits the market by treatment (IV Ketamine, Intranasal Esketamine, Ketamine-Assisted Psychotherapy), indication (Depression, PTSD, Chronic Pain, Anxiety) and end user (Hospitals, Clinics, Home Care, Corporate and Payer Clients).
Who are the key players in the Ketamine Clinics market?
Key players include Johnson & Johnson, Klarity Health, Mindbloom, Nushama and Novamind.
What is driving the Ketamine Clinics market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the ketamine Clinics market. Governments and employers are investing more in mental health care.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on Ketamine Clinics are running in the US?
50 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
What does WHO report for the US?
Suicide rate: 14.0 per 100,000 people in 2023, the latest WHO figure. Source: WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.
How many people in the US are 65 or older?
18.4% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 18 Nov 2026.
How much research is published on Ketamine Clinics?
PubMed lists 12 papers on Ketamine Clinics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.